Literature DB >> 8970450

Cerebral hemodynamics in preeclampsia and eclampsia.

A I Qureshi1, M R Frankel, J R Ottenlips, B J Stern.   

Abstract

OBJECTIVE: To test further the hypothesis that preeclampsia and eclampsia are associated with cerebral vasospasm.
DESIGN: Prospective case study.
SETTING: Inpatient obstetrics service of an urban public hospital. PATIENTS AND METHODS: Eleven women with eclampsia (mean gestational age, 32 weeks), preeclampsia (mean gestational age, 36 weeks), or normotensive pregnancy (mean gestational age, 35 weeks). Middle cerebral artery (MCA) velocity was measured bilaterally in all patients by means of transcranial Doppler ultrasonography.
RESULTS: Eclamptic patients (n = 3) had significantly higher mean flow velocities and lower average pulsatility indexes than did normotensive patients (n = 4) (average MCA-mean flow velocity, 165 vs 79 cm/s [P = .007]; average MCA pulsatility index, 0.51 vs 1.1 [P < .001]). Compared with normotensive pregnant women, preeclamptic patients (n = 4) had lower average pulsatility indexes (0.76, P = .003), but similar mean flow velocities (average MCA-mean flow velocity, 82 cm/s; P = .8).
CONCLUSION: Significantly higher MCA velocities in eclamptic, but not preeclamptic, women compared with those in normotensive pregnant women suggests that moderate to severe vasospasm is associated with eclampsia.

Entities:  

Mesh:

Year:  1996        PMID: 8970450     DOI: 10.1001/archneur.1996.00550120034013

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  11 in total

1.  Atypical reversible eclamptic encephalopathy: utility of diffusion weighted MRI and ADC values.

Authors:  Man Seok Park; Tae Seung Nam; Seung Han Lee; Byeong Chae Kim; Myeong Kyu Kim; Ki Hyun Cho
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

Review 2.  Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-10       Impact factor: 3.825

3.  Usefulness of ultrasonography in posterior reversible encephalopathy syndrome.

Authors:  Piergiorgio Lochner; Cornelia Mader; Raffaele Nardone; Roberto Cantello; Andrea Orioli; Francesco Brigo
Journal:  Neurol Sci       Date:  2013-10-17       Impact factor: 3.307

4.  Autonomic dysreflexia-induced reversible posterior leukoencephalopathy syndrome in patients with spinal cord injury: two case reports.

Authors:  Kyung-Lim Joa; Yong-Il Shin; Huy Suh; Soo-Yeon Kim; Jae Hyeok Chang; Hyun-Yoon Ko
Journal:  J Spinal Cord Med       Date:  2013-05       Impact factor: 1.985

5.  Reversible posterior encephalopathy syndrome associated with late onset postpartum eclampsia: A case report.

Authors:  Qi-Yu Bo; Xiu-He Zhao; Xue Yang; Sheng-Jun Wang
Journal:  Exp Ther Med       Date:  2016-07-20       Impact factor: 2.447

6.  Cerebral vasospasm and intracerebral haemorrhage in a case of pregnancy-related thrombotic thrombocytopoenic purpura/haemolytic uraemic syndrome.

Authors:  I C Duncan
Journal:  Interv Neuroradiol       Date:  2005-10-25       Impact factor: 1.610

7.  Cerebrovascular Disease in Pregnancy.

Authors:  Michael A. Sloan; Barney J. Stern
Journal:  Curr Treat Options Neurol       Date:  2003-09       Impact factor: 3.598

8.  Cerebrovascular Reactivity and Vascular Activation in Postmenopausal Women With Histories of Preeclampsia.

Authors:  Jill N Barnes; Ronée E Harvey; Kathleen B Miller; Muthuvel Jayachandran; Katherine R Malterer; Brian D Lahr; Kent R Bailey; Michael J Joyner; Virginia M Miller
Journal:  Hypertension       Date:  2017-11-20       Impact factor: 10.190

Review 9.  A case of postpartum cerebral angiopathy with subarachnoid hemorrhage.

Authors:  Yolanda Chik; Robert E Hoesch; Christos Lazaridis; Carla J Weisman; Rafael H Llinas
Journal:  Nat Rev Neurol       Date:  2009-09       Impact factor: 42.937

Review 10.  Advances in the understanding of eclampsia.

Authors:  S Ananth Karumanchi; Marshall D Lindheimer
Journal:  Curr Hypertens Rep       Date:  2008-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.